PROBLEM

Currently, metastatic cancer disease is frequently considered incurable. In fact, 90% of mortalities of cancer patients are caused by distant tumor metastases to the lungs, bones, lymph nodes, liver, and other organs.

SOLUTION

Biotech startup K-Lab Therapeutics is developing novel immunotherapies targeting myeloid-derived suppressor cells (MDSCs) and cancer cells to cure advanced and metastatic cancers.

Our preclinical studies provide solid evidence for the successful therapy of the kidney and bladder cancer metastases to the lungs. Taking into account the mechanism of action for our therapy, there is a hope that the other cancer types also will respond to our anti-metastatic treatment.

We identified a novel molecular target for cancer immunotherapy. We developed novel, effective immuno-oncology drugs that can overcome resistance to cancer immunotherapy by targeting both tumor cells and myeloid-derived suppressor cells. Our current focus is on validating a unique pipeline of first-in-class cancer immunotherapies in the form of novel antibody-drug conjugates (ADC) and CAR-T cells.